Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficiently explored. we conducted this real-life retrospective multicentric observational study to assess the effectiveness of tildrakizumab in elderly patients with moderate-to-severe psoriasis, with involvement of difficult-to-treat areas.materials and methods: we enrolled forty-nine patients aged 65 years old or more (mean age 73.1 +/- 6.0), all treated with tildrakizumab for at least 28 weeks. the effectiveness of tildrakizumab was assessed by static physician's global assessment of genitalia (sPGA-G), fingernail-PGA (f-PGA), palmoplantar PGA (pp-PGA), scalp-specific PGA (sc-PGA), and psoriasis area and Severity Index (PASI) scores.results: significant improvements in PASI scores were observed within 28 weeks of treatment, with 77.5%, 60%, and 45.2% of patients achieving PASI75, PASI90, and PASI100, respectively. the mean PASI decreased significantly from baseline (13.6 +/- 9.9) to 1.3 +/- 1.7 at week 28. more than 90% of patients had clear sPGA-G and pp-PGA scores and over 70% had clear f-PGA and sc-PGA scores after 28 weeks.conclusions: our findings suggest that tildrakizumab could be a valuable option for the treatment of elderly patients, including those with difficult-to-treat areas involvement.